How to buy ResMed shares
Own ResMed shares in just a few minutes.
ResMed Inc is a medical instruments & supplies business based in Australia. ResMed shares (RMD) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. ResMed has a trailing 12-month revenue of around $3 billion.
How to buy shares in ResMed
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for ResMed. Find the share by name or ticker symbol: RMD. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ResMed reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $N/A, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of ResMed. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
ResMed share priceUse our graph to track the performance of RMD stocks over time.
ResMed shares at a glance
|52-week range||AUDA$18.4 - AUDA$29.3|
|50-day moving average||AUDA$24.4931|
|200-day moving average||AUDA$25.0976|
|Dividend yield||AUDA$0.22 (0.89%)|
|Earnings per share (TTM)||AUDA$0.427|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy ResMed stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is ResMed under- or over-valued?
Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ResMed's P/E ratio
ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, ResMed shares trade at around 40x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ResMed's PEG ratio
ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.1006. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $922.9 million.
The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3 billion|
|Operating margin TTM||27.36%|
|Gross profit TTM||$1.8 billion|
|Return on assets TTM||11.63%|
|Return on equity TTM||27.21%|
|Market capitalisation||$33.9 billion|
TTM: trailing 12 months
ResMed share dividends
Dividend payout ratio: 27.4% of net profits
Recently ResMed has paid out, on average, around 27.4% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.89% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0.89% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about A$0.22 per share.
While ResMed's payout ratio might seem fairly standard, it's worth remembering that ResMed may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 18 August 2020 (the "ex-dividend date").
Have ResMed's shares ever split?
ResMed's shares were split on a 2:1 basis on 11 August 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.
ResMed share price volatility
Over the last 12 months, ResMed's shares have ranged in value from as little as $18.4 up to $29.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while ResMed's is 0.3584. This would suggest that ResMed's shares are less volatile than average (for this exchange).
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Frequently asked questions
Ask an Expert